BioTissue
PrivateLast Round
Series C
Jun 26, 2019
Total Funding Raised
$117.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BioTissue is a biotechnology company that develops and commercializes regenerative medicine products derived from human amniotic membrane and umbilical cord tissues for ocular, surgical, and wound care applications.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioTissue Comparables
Compare BioTissue with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Merakris Therapeutics | 85% | |
| NuVision Biotherapies | 83% | |
| Surgenex | 83% |
BioTissue Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 26, 2019 | ||||
| Series B | Jun 23, 2015 | ||||
| Debt | May 12, 2015 | ||||
| Growth Equity | Aug 22, 2013 |
BioTissue Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EW Healthcare Partners | Series C |
| Square 1 Bank | Debt |
| Ballast Point Ventures | Growth Equity, Series C, Series B |
| RC Capital | Growth Equity, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 46% MoM.
- Jan 23, 2026
Acquiring surgical and wound care business for up to $40 million.
Recent news
Latest coverage and updates
- recognized_asOct 16, 2026
BioTissue, Inc. ranks #21 on the 2026 Fortune Best Workplaces in BioPharma list, presented by Great Place to Work and Fortune magazine, for the third consecutive year in Florida on Oct 16th '26.
- hiresOct 6, 2026
BioTissue, Inc. appoints Rocco Venezia, CPA, as Chief Financial Officer in Florida on Oct 5th '26, succeeding Mike Cornelius, who retires after 13 years with the company.
- hiresAug 24, 2026
BioTissue, Inc. hired Chris Calcaterra as independent director on Aug 24th '26.
BioTissue Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about BioTissue's valuation, stock price, and market status.
Is BioTissue a public or private company?
BioTissue is a private company.
What is the current stock price of BioTissue?
BioTissue is a private company, so its shares have no public market price. Caplight tracks BioTissue's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioTissue worth (valuation)?
Valuation information for BioTissue is not publicly available.
Can I buy BioTissue stock?
BioTissue shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioTissue's last funding round?
BioTissue's most recent funding round was Series C on June 26, 2019.
Who are the main investors in BioTissue?
Key investors in BioTissue include EW Healthcare Partners, Ballast Point Ventures, RC Capital.
Will BioTissue IPO soon?
No public IPO plans have been announced for BioTissue.
How can I track BioTissue secondary market activity?
Caplight tracks bids, offers, and trades in BioTissue's shares on secondary markets.